Chest pain is the prevalent symptom at presentation in patients with acute myocardial infarction (AMI). Despite the complete absence of rigorous studies designed to assess the impact of morphine administration in patients with AMI, clinical practice guidelines strongly recommend morphine for analgesia. However, when using morphine to relieve chest pain in AMI patients, physicians must be aware that hypotension, respiratory depression, vomiting, and delayed onset of action of antiplatelet agents are potential unwanted side effects of the drug. The purpose of this report is to review morphine's clinical and side effects and to propose strategies able to reduce chest pain in AMI patients.
Introduction
Chest pain is the prevalent symptom at presentation in patients with acute myocardial infarction (AMI). Pain characteristics are highly subjective, and symptom severity and emotional consequences may vary widely. 1, 2 An asymptomatic AMI is not necessarily less severe than a symptomatic event. Diabetic and elderly subjects are those who generally present with a lower severity of chest pain and at the same time represent the subgroups of AMI patients with worse outcome. 3 Chest pain severity over time may also change in relation to the presence and severity of myocardial ischaemia, which depends on multiple factors influencing the relationship between oxygen supply and demand in the myocardium at risk. Oxygen supply during the acute phase of AMI depends not only on permanent or intermittent occlusion of the culprit coronary vessel but also on the development of potentially effective collateral circulation and on the blood oxygen content. At the same time, oxygen demand depends on ventricular wall stress and contractility and on heart rate. 2
Guideline-based therapy for STEMI
Relief of pain may be of paramount importance, not only for humane reasons but also because the pain may be associated with sympathetic activation, which increases the workload of the heart. Thus, a rationale exists to relieve or to reduce chest pain in AMI patients.
Current American College of Cardiology/American Heart Association guidelines for the management of patients with ST-elevation acute myocardial infarction (STEMI) 4 state that intravenous morphine sulphate is the drug of choice for pain relief in patients with STEMI, and thus it should be routinely used in these patients. Moreover, in AMI patients with pulmonary oedema (Killip Class III), intravenous morphine relieves anxiety and may reduce dyspnoea. However, nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors are contraindicated in these patients, since epidemiological studies and retrospective analyses of randomized trials have suggested that the use of these agents may be associated with an increased risk of death and adverse outcomes. 4 The same guidelines recommend the use of intravenous beta-blockers and nitrates in patients with ongoing ischaemia (chest pain) and hypertension if no contraindication. As is well known, betablockers should not be used in patients with heart failure, cardiogenic shock and high-grade atrio-ventricular block, while nitrates should be avoided in patients with suspected right ventricular infarction, hypotension, and recent use of 5'-phosphodiesterase inhibitors. Similarly, the European Society of Cardiology (ESC) guidelines for the management of STEMI patients recommend intravenous opioids (e.g. morphine) for relief of pain with a class I indication and a level of evidence C. 5 In the ESC document, intravenous beta-blockers and nitrates are not routinely recommended, but they should be considered in selected STEMI patients without contraindications.
Thus, despite the complete absence of rigorous studies designed to assess the impact of morphine administration in patients with AMI, clinical practice guidelines for the management of patients with STEMI strongly recommend the use of morphine for analgesia. 4, 5 This recommendation is only derived from expert opinion.
We must also consider that morphine was introduced among treatments of patients with AMI in the 1960s, before the wide use of reperfusive strategies. 6 Big changes have occurred in the treatment of STEMI patients in the last 50 years. In the meantime, there have been no prospective studies evaluating the use of morphine for this indication. Nowadays, with the development of networks dedicated to AMI treatment, it is possible to promptly manage the cause rather than simply mask ischaemic cardiac pain.
Clinical effects of morphine
Opioids are highly effective drugs in controlling pain. Morphine has been used for centuries to treat human pain. It has been reported that in 1805 a German pharmacist named Friedrich Wilhelm Sertürner isolated a pharmacologically active ingredient from a plant. This alkaloid was initially used for insomnia treatment, and it was named morphine, since Morpheus was the god of dreams in Greek mythology. 7 The analgesic effect of opioids derives from the fact that they mimic the actions of a series of brain peptides by binding to a number of different specific types of cellular receptor, each mediating distinctive actions, with subsequent activation of endogenous pain-modulating systems. At least three cellular receptor subtypes (μ, κ, and δ) are responsible for the reported effects of the opioids. The majority of morphine's clinical effects have been attributed to interaction with the μ receptors, which are mainly located in the brain and in the gastro-intestinal tract. The activation of the μ receptors in the brain is responsible for analgesia, sedation, respiratory depression and euphoria. Hypoventilation may foster hypoxaemia, which is definitely an unwanted event in AMI patients. On the other hand, the activation of the opioid receptors located in the myenteric plexus and the intestines may affect the gastro-intestinal tract's physiological functions. In particular, morphine delays the transit time from the stomach to the intestine and reduces intestinal and pancreatic secretions. Moreover, nausea and vomiting are also common side effects of morphine. The vomiting mechanism is not completely understood. However, the interaction with μ receptors in the chemoreceptor trigger zone and the vomiting centre in the medulla is thought to play an important role. 8 Finally, little is known about the optimal dose of intravenous morphine in AMI patients. Higher morphine doses may cause vasodilation and hypotension, 6 the latter being an inconvenient side effect in AMI patients. Generally speaking, when using morphine, the goal of therapy should be to use the lowest effective dose with minimal side effects. Repeated low-dose therapy is advisable. 4, 5 Physicians should also have in mind that an opioid receptor antagonist such as naloxone (0.1 to 0.2 mg i.v. every 15 min) can be used to acutely reverse the effect of systemic opioids.
Morphine-antiplatelet interaction
Concerns exist that morphine may increase mortality in the setting of non-ST elevation AMI. In the CRUSADE registry, based on 57,039 subjects with acute coronary syndrome without ST elevation, patients treated with morphine (n=17,003) had a higher adjusted risk of death (odds ratio (OR) 1.48, 95% confidence interval (CI) 1.33-1.64) than patients not treated with morphine. Using a propensity score matching method, morphine was still associated with increased in-hospital mortality (OR 1.41, 95% CI 1.26-1.57). 9 Of note, this study was not randomized, and a potential mechanism linking morphine use with the unfavourable outcome has not been demonstrated. The hypothesis that morphine was administered to higher-risk patients is also to be considered.
An additional potential explanation of morphine's negative impact on AMI outcome may be, at least in part, related to drug-to-drug interactions. In fact, in patients with AMI a significant number of drugs are usually administered, thereby raising the risk for drug-to-drug interactions. Antiplatelet agents are the mainstay of pharmacological treatment in patients presenting with an acute coronary syndrome, including STEMI. In a small study aiming to investigate the onset time of the novel P2Y 12 receptor inhibitors (i.e. prasugrel and ticagrelor) in STEMI patients, a delayed antiplatelet effect due to morphine use has been hypothesized. 10 A biologically plausible causeeffect relation may exist, given that morphine inhibits gastric emptying, thereby delaying absorption and possibly resulting in decreased peak plasma levels of orally administered drugs. 11 The association between morphine use and delayed onset of action of the oral antiplatelet agents has been confirmed in two further pharmacodynamic studies based on STEMI patients. 12, 13 Moreover, a small recent pharmacokinetic study in 24 healthy volunteers documented that morphine delays clopidogrel absorption and decreases plasma levels of clopidogrel active metabolite. 14 Finally, in a broader multicentre study based on 300 STEMI patients undergoing primary percutaneous coronary intervention (PCI) and receiving either prasugrel or ticagrelor loading doses, the drug-to-drug interaction between morphine and antiplatelet agents was definitely documented. 15 In this study, the negative impact of morphine on platelet inhibition was not only confined to when vomiting occurred as a side effect, since after patients with vomiting were excluded, morphine-treated subjects clearly showed higher residual platelet reactivity as compared with subjects who did not receive morphine. The effect was consistent with both prasugrel and ticagrelor. Thus, the morphine-antiplatelet agent interaction is likely a non-drug-specific phenomenon related to the inhibition of the normal muscular activity of the stomach and the intestines, which may lead to vomiting or delayed gastric emptying, which in turns reduces absorption and decreases peak plasma levels of orally administered drugs. We may also hypothesize that patients who received morphine might be subjects at higher risk. Thus, it is possible that in sicker patients, haemodynamic derangement, adrenergic activation, and systemic vasoconstriction with the reduction of blood volume to the abdomen may contribute to the delayed drug adsorption and to the reduced platelet inhibition.
As a matter of fact, in the Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) Trial, STEMI patients who did not receive morphine had a significant improvement in the ECG-based primary end point (potentially reflecting better myocardial reperfusion), with a significant p value for interaction between morphine use and time of ticagrelor administration. 16 Suboptimal platelet inhibition early after primary stent implantation for STEMI is associated with thrombotic complications, including stent thrombosis. 17 Given the key importance of platelet inhibition in patients treated by coronary stenting for STEMI and the absence of data that may support a potential clinical benefit of morphine in patients with AMI, more caution should be used regarding morphine administration, and a selective rather than routine morphine use seems to be reasonably recommended in STEMI patients. If early optimal platelet inhibition is deemed necessary, intravenous antiplatelet agents such as glycoprotein IIb/IIIa receptor inhibitors or cangrelor should be considered in STEMI patients, especially after morphine administration.
Severe chest pain has been previously defined as a "selfreported" numeric rating scale ⩾ 7, 18 based on a scale from 0 to 10. Morphine administration might be reserved for AMI patients presenting persistent severe chest pain. Reducing the number of STEMI patients treated with morphine may translate into the global limitation of the aforementioned drug-to-drug interaction, and the reduction of opioid-related respiratory depression, which may lead to diminution of myocardial oxygen delivery.
Alternative strategies to reduce pain
Other strategies beside morphine may reduce chest pain levels in STEMI patients. The list of drugs potentially able to influence chest pain in AMI patients is reported in Table  1 . It should be considered that in patients with less severe chest pain, intravenous paracetamol (1 g) or aspirin (⩾300 mg) is able to reduce chest pain. 19 In addition, early administration of aspirin (in association with heparin) results in a higher rate of initial infarct-related artery patency, 20 consequently reducing chest pain in a significant proportion of patients. Moreover, it has long been documented that betablockers 21 and nitrates 22 are able to reduce AMI-related chest pain. Finally, myocardial ischaemia relief (i.e. reperfusion) should be considered the definitive chest pain control strategy. 23 Thus, selective use of intravenous morphine could be an appropriate therapy for AMI patients who continue to report severe symptoms related to myocardial ischaemia (i.e. chest pain) despite initial therapy based on aspirin (with or without heparin) and anti-ischaemic drugs. 24 The strategy of using morphine after early treatment with intravenous metoprolol in patients with suspected AMI has been evaluated in a previous study, which documented that if chest pain persists after intravenous beta-adrenergic blockade treatment, standard doses of morphine offer better pain relief than increased dosages of metoprolol. 25 In addition, a recent trial showed that in patients with anterior Killip class <III STEMI undergoing primary PCI, early intravenous metoprolol administered before reperfusion may result in outcome improvements including reduced infarct size, higher long-term left ventricular function, reduced incidence of severe left ventricular systolic dysfunction and implantable cardioverter defibrillator indications, and fewer heart failure admissions. 26 Interestingly, the recently presented Air Versus Oxygen in ST-Elevation Myocardial infarction (AVOID) trial 27 suggested that supplemental oxygen therapy does not reduce ongoing ischaemia in STEMI patients, but, contrarily, it may be harmful in subjects who are not hypoxic, since supplemental oxygen was associated with increased myocardial injury and infarct size, recurrent myocardial infarction, and major cardiac arrhythmia.
With all this as a background, a proposed strategy of chest pain management in STEMI patients is reported in Figure 1 . Restricted (selective) morphine use may be reserved for patients presenting with persistent severe chest pain (numeric rating scale ⩾ 7) after initial administration of antithrombotic and anti-ischaemic therapies. Myocardial reperfusion strategies, preferably primary PCI, should be performed as soon as possible, allowing prompt cessation of myocardial ischaemia and chest pain.
Conclusions
When using morphine to relieve chest pain in AMI patients, physicians must be aware that hypotension, respiratory depression, vomiting, and delayed onset of action of antiplatelet agents are potential unwanted side effects of the drug. Thus, the use of morphine could be reserved for patients with persistent severe chest pain after the administration of drugs that favourably alter myocardial oxygen supply and demand while waiting for timely reperfusion. Prospective, randomized clinical trials are needed to determine whether and how morphine should be administered to patients with chest pain and AMI.
